If you are citizen of an European Union member nation, you may not use this service unless you are at least 16 years old.
You already know Dokkio is an AI-powered assistant to organize & manage your digital files & messages. Very soon, Dokkio will support Outlook as well as One Drive. Check it out today!

Gene Therapy and SB-728T (redirected from Atheel - Gene Therapy and SB-728T)

Page history last edited by Yako, Atheel 11 years, 5 months ago

Thesis: SB-728-T is a treatment that is in development under Gene Therapies that aims to produce HIV resistant cells. When approved, there would be no need for HAART.

-Gene Therapy:

1. What is Gene Therapy?

Uses DNA as a way to treat diseases.
Introduces genetic material into a patient's cell to turn certain functions off for (HIV negative patients) or on for (HIV positive patients).

- SB-728T: Zinc Finger DNA Protein Transcription Factor

Aims to modify gene encoding CCR5. This gene is responsible for making the co-receptor needed in order for HIV to infect cells.

1. CD4 cells are the only cells able to become infected with HIV

-On the surface of CD4 cells, there is protein CCR5 that acts as a co-receptor. HIV can only enter and infect the cell using this co-receptor.

2. Disrupts the formation of CCR5 co-receptors.

3. Without these co-receptors, HIV can not infect the cells.

4. Experimental/clinical results are still in development.

5. Aim is to produce a population of HIV resistant cells.

6. Development of SB-728T would make anti-retroviral therapies unnecessary because the CD4 cells would be resistant to HIV infection.

7. For the rest of the development, research on SB-728T is focused on:

- Safety of the treatment.

- Effect of SB-728T when working with or after the treatment of HAART.

- Long term effects of the treatment.

Even though this vaccine will be approved in two months, and it will be able to produce HIV resistant cells eventually eliminating the need for HAART, SB-728T will only benefit the HIV negative patients.